<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04094766</url>
  </required_header>
  <id_info>
    <org_study_id>XJTU-BLLCAR-L10D</org_study_id>
    <nct_id>NCT04094766</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia</brief_title>
  <official_title>A Phase I Clinical Study of Dual Specificity CD19 and CD22 Chimeric Antigen Receptor T Cell Therapy in Relapsed or Refractory Acute B Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanjing Legend Biotech Co.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital of Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, dose escalation clinical study to evaluate the safety and&#xD;
      efficacy of infusion of dual specificity CD19 and CD22 CAR-T cells in patients with relapsed&#xD;
      and refractory acute B lymphoblastic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CD19-directed CAR-T cell therapy has shown promising results for the treatment of relapsed or&#xD;
      refractory acute B lymphoblastic leukemia. CD19 and CD22 are proteins usually expressed on&#xD;
      the surface of the B leukemia cells. The dual specificity CAR enables the T-cells to&#xD;
      recognize and kill the tumor cell through recognition of CD19 and CD22.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Production plan adjustment&#xD;
  </why_stopped>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of treatment related adverse events</measure>
    <time_frame>Day 1-100 days after injection</time_frame>
    <description>Assessed by CTCAE v4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Day 1-5 years after injection</time_frame>
    <description>Objective response include complete remission and partial remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Day 1-5 years after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Day 1-5 years after injection</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Copy numbers of CAR-T cells in patients</measure>
    <time_frame>Day 1-5 years after injection</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Refractory B Acute Lymphoblastic Leukemia</condition>
  <condition>Relapse B Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>BLLCAR-L10D treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In BLLCAR-L10D treatment group, patients will be treated with dual specificity CD19 and CD22 CAR-T cells with a escalation approach, 3 CAR-T dosage will be tested in this study: 0.5×10^6, 1.5×10^6, 2.0×10^6 CAR-T cells/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy</intervention_name>
    <description>Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy by intravenous injection.</description>
    <arm_group_label>BLLCAR-L10D treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent could be acquired;&#xD;
&#xD;
          2. Diagnosed with relapse/refractory acute lymphoblastic leukemia;&#xD;
&#xD;
          3. Relapse was defined as recurrence of blast cell(more than 5%) in peripheral blood or&#xD;
             in bone marrow or extramedullary involvement;&#xD;
&#xD;
          4. Refractory was defined as failed to achieve complete remission after two courses of&#xD;
             induction therapy;&#xD;
&#xD;
          5. CD19/CD22 postive leukemia cell was confirmed by flow cytometry or&#xD;
             immunohistochemistry within 90 days since enrollment in this trial;&#xD;
&#xD;
          6. Karnofsky score ≥70;&#xD;
&#xD;
          7. Results of pregnant test should be negative, and agree to conception control during&#xD;
             treatment and 6 months after CAR-T infusion.&#xD;
&#xD;
          8. Adequate organ function: EF≥50%; normal ECG; CCR ≥ 50ml/min or Cr &lt; 2.0mg/dL or &lt; 2&#xD;
             times upper limitation of normal; ALT and AST&lt;5 times upper limitation of normal;&#xD;
             Serum bilirubin ≤ 3.0mg/dL; DLCO or FEV1 &gt; 45% of predict value;&#xD;
&#xD;
          9. At least 2 weeks intervals since the last chemotherapy;&#xD;
&#xD;
         10. At least 2 weeks intervals since the last anti-GVHD therapy if patients have ever ;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients diagnosed with acute promyelocytic leukemia:t(15;17)(q22;q12);&#xD;
&#xD;
          2. Women in pregnancy and lactation;&#xD;
&#xD;
          3. Uncontrolled infection, Active HBV or HCV infection, HIV positive or any other deadly&#xD;
             bacterial/virual diseases;&#xD;
&#xD;
          4. Long term use of systemic corticosteroids(5mg per day for 2 weeks);&#xD;
&#xD;
          5. Any other uncontrolled life-threaten diseases;&#xD;
&#xD;
          6. Patients with history of anaphylaxis to any drugs;&#xD;
&#xD;
          7. With central nervous system (CNS) involvement;&#xD;
&#xD;
          8. Patients with GVHD after allo-HSCT who needed immunosuppressive agents ;&#xD;
&#xD;
          9. Patients with acute autoimmune diseases such as psoriasis or rheumatoid arthritis;&#xD;
&#xD;
         10. Other conditions that principle investigator considered may increase the risk of the&#xD;
             patients or interference the results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aili He, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital of Xi'an Jiaotong University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 17, 2019</study_first_submitted>
  <study_first_submitted_qc>September 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chimeric Antigen Receptor T cells</keyword>
  <keyword>CD19 and CD22</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

